News

Home Depot disappoints, Novo Nordisk's GLP-1 updates, an AI warning and more in Morning Squawk

Home Depot kicked off this week's string of retailer earnings reports. Novo Nordisk provided two major updates on its ...

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

GoodRx CEO discusses GLP-1 deal with Novo Nordisk: What to know

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...
Fierce Pharma1d

Novo Nordisk unveils $499 cash-pay Ozempic offering amid continued compounder competition

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

One in four US adults with diabetes used a GLP-1 drug last year, survey finds

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

Novo Nordisk: The Falling Knife That Keeps Giving

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...